
    
      The study consisted of two periods: a screening period of 1 week and a double-blind treatment
      period (8 weeks). After the screening period, 588 enrolled subjects were randomized into one
      of 3 study groups in the 1:1:1 ratio, 2 LY03005 treatment groups with different dose or 1
      placebo group. Subjects were given investigatory drug or placebo according to the protocol,
      followed up at the end of 1, 2, 4 6, and 8 weeks.
    
  